七叶树籽提取物:创造基于证据的新天然产品的机会

Q3 Pharmacology, Toxicology and Pharmaceutics
Poonam N. Chougule, M. Tayade, N. Chougule
{"title":"七叶树籽提取物:创造基于证据的新天然产品的机会","authors":"Poonam N. Chougule, M. Tayade, N. Chougule","doi":"10.25258/ijpqa.14.2.33","DOIUrl":null,"url":null,"abstract":"For centuries, herbal remedies have been used to prevent and treat disease. Horse chestnut seeds are an abundant source of phytoconstituents containing triterpenoid saponins, with thirty molecules isolated and characterized. Escin, which is a combination of acylated triterpene glycosides composed of α- and β-escin, is the major biologically active component of horse chestnut seed extract. Escin is the most researched veno-active compound with anti-inflammatory, anti-oedematous, and antioxidant properties. Due to their unique three pharmacological actions, escin is a well-established molecule for the management of venous diseases such as chronic venous insufficiency (CVI) and hemorrhoids. The available treatments for CVI have some disadvantages, including severe side effects, expensive surgical options, long duration of treatment, and limited accessibility to allopathic drugs. As a result, phytoconstituents and lifestyle changes can be seen as safe and effective therapy options for CVI management because they have no major side effects and can simultaneously function on several targets. This review article focuses on the chemical components of horse chestnut extract, particularly the phytoconstituents escin, and proanthocyanidins, which have been extensively studied in preclinical and clinical studies. The review article provides a comprehensive overview of their potential therapeutic benefits in managing symptoms of CVI and their regulatory status.","PeriodicalId":14260,"journal":{"name":"International Journal of Pharmaceutical Quality Assurance","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Horse Chestnut Seed Extract: An Opportunity for Creating Evidencebased New Natural Products\",\"authors\":\"Poonam N. Chougule, M. Tayade, N. Chougule\",\"doi\":\"10.25258/ijpqa.14.2.33\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"For centuries, herbal remedies have been used to prevent and treat disease. Horse chestnut seeds are an abundant source of phytoconstituents containing triterpenoid saponins, with thirty molecules isolated and characterized. Escin, which is a combination of acylated triterpene glycosides composed of α- and β-escin, is the major biologically active component of horse chestnut seed extract. Escin is the most researched veno-active compound with anti-inflammatory, anti-oedematous, and antioxidant properties. Due to their unique three pharmacological actions, escin is a well-established molecule for the management of venous diseases such as chronic venous insufficiency (CVI) and hemorrhoids. The available treatments for CVI have some disadvantages, including severe side effects, expensive surgical options, long duration of treatment, and limited accessibility to allopathic drugs. As a result, phytoconstituents and lifestyle changes can be seen as safe and effective therapy options for CVI management because they have no major side effects and can simultaneously function on several targets. This review article focuses on the chemical components of horse chestnut extract, particularly the phytoconstituents escin, and proanthocyanidins, which have been extensively studied in preclinical and clinical studies. The review article provides a comprehensive overview of their potential therapeutic benefits in managing symptoms of CVI and their regulatory status.\",\"PeriodicalId\":14260,\"journal\":{\"name\":\"International Journal of Pharmaceutical Quality Assurance\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutical Quality Assurance\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25258/ijpqa.14.2.33\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Quality Assurance","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25258/ijpqa.14.2.33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

几个世纪以来,草药一直被用来预防和治疗疾病。七叶树种子是一种富含三萜皂苷的植物成分,已分离并鉴定了30个分子。Escin是由α-和β-escin组成的酰化三萜苷,是七叶树籽提取物的主要生物活性成分。叶esin是研究最多的静脉活性化合物,具有抗炎、抗水肿和抗氧化特性。由于其独特的三种药理作用,叶绿素是治疗慢性静脉功能不全(CVI)和痔疮等静脉疾病的公认分子。CVI的现有治疗方法有一些缺点,包括严重的副作用、昂贵的手术选择、治疗持续时间长,以及对抗药物的可及性有限。因此,植物成分和生活方式的改变可以被视为CVI管理的安全有效的治疗选择,因为它们没有主要的副作用,并且可以同时对几个目标起作用。本文综述了七叶树提取物的化学成分,特别是在临床前和临床研究中被广泛研究的植物成分叶esin和原花青素。这篇综述文章全面概述了它们在控制CVI症状方面的潜在治疗益处及其调节状态。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Horse Chestnut Seed Extract: An Opportunity for Creating Evidencebased New Natural Products
For centuries, herbal remedies have been used to prevent and treat disease. Horse chestnut seeds are an abundant source of phytoconstituents containing triterpenoid saponins, with thirty molecules isolated and characterized. Escin, which is a combination of acylated triterpene glycosides composed of α- and β-escin, is the major biologically active component of horse chestnut seed extract. Escin is the most researched veno-active compound with anti-inflammatory, anti-oedematous, and antioxidant properties. Due to their unique three pharmacological actions, escin is a well-established molecule for the management of venous diseases such as chronic venous insufficiency (CVI) and hemorrhoids. The available treatments for CVI have some disadvantages, including severe side effects, expensive surgical options, long duration of treatment, and limited accessibility to allopathic drugs. As a result, phytoconstituents and lifestyle changes can be seen as safe and effective therapy options for CVI management because they have no major side effects and can simultaneously function on several targets. This review article focuses on the chemical components of horse chestnut extract, particularly the phytoconstituents escin, and proanthocyanidins, which have been extensively studied in preclinical and clinical studies. The review article provides a comprehensive overview of their potential therapeutic benefits in managing symptoms of CVI and their regulatory status.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
International Journal of Pharmaceutical Quality Assurance
International Journal of Pharmaceutical Quality Assurance Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
0.80
自引率
0.00%
发文量
0
期刊介绍: INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE is a quarterly international journal publishing the finest peer-reviewed research in the field of Pharmaceutical Quality Assurance and Pharmaceutical Analysis on the basis of its originality, importance, disciplinary interest, timeliness, accessibility, elegance, and surprising conclusions. IJPQA also provides rapid, authoritative, insightful and arresting news and interpretation of topical and coming trends affecting science, scientists and the wider public.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信